Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review
- Author(s)
- Kinsella, PM; Moso, MA; Morrissey, CO; Dendle, C; Guy, S; Bond, K; Sasadeusz, J; Slavin, MA;
- Journal Title
- Transplant Infectious Disease
- Publication Type
- Review
- Abstract
- Antiviral agents with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have played a critical role in disease management; however, little is known regarding the efficacy of these medications in the treatment of SARS-CoV-2 infection in immunocompromised patients, particularly in the management of persistent SARS-CoV-2 positivity. This narrative review discusses the management of persistent coronavirus disease 2019 in immunocompromised hosts, with a focus on antiviral therapies. We identified 84 cases from the literature describing a variety of approaches, including prolonged antiviral therapy (n = 11), combination antivirals (n = 13), and mixed therapy with antiviral and antibody treatments (n = 60). A high proportion had an underlying haematologic malignancy (n = 67, 80%), and were in receipt of anti-CD20 agents (n = 51, 60%). Success was reported in 70 cases (83%) which varied according to the therapy type. Combination therapies with antivirals may be an effective approach for individuals with persistent SARS-CoV-2 positivity, particularly those that incorporate treatments aimed at increasing neutralizing antibody levels. Any novel approaches taken to this difficult management dilemma should be mindful of the emergence of antiviral resistance.
- Publisher
- Wiley
- Keywords
- SARS‐CoV‐2; antibody; antiviral; immunocompromised; persistent; prolonged
- Department(s)
- Infectious Diseases
- Publisher's Version
- https://doi.org/10.1111/tid.14301
- Open Access at Publisher's Site
https://doi.org/10.1111/tid.14301- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-07-11 01:41:19
Last Modified: 2024-07-11 01:48:04